Public Employees Retirement Association of Colorado Sells 2,490 Shares of EXACT Sciences Co. (NASDAQ:EXAS)

Share on StockTwits

Public Employees Retirement Association of Colorado reduced its position in shares of EXACT Sciences Co. (NASDAQ:EXAS) by 11.9% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 18,468 shares of the medical research company’s stock after selling 2,490 shares during the period. Public Employees Retirement Association of Colorado’s holdings in EXACT Sciences were worth $2,180,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the company. Janus Henderson Group PLC grew its holdings in shares of EXACT Sciences by 426.1% during the second quarter. Janus Henderson Group PLC now owns 27,288 shares of the medical research company’s stock worth $3,221,000 after purchasing an additional 22,101 shares during the last quarter. Aperio Group LLC grew its holdings in shares of EXACT Sciences by 26.3% during the second quarter. Aperio Group LLC now owns 28,013 shares of the medical research company’s stock worth $3,306,000 after purchasing an additional 5,834 shares during the last quarter. Great Valley Advisor Group Inc. lifted its stake in shares of EXACT Sciences by 32.1% in the second quarter. Great Valley Advisor Group Inc. now owns 12,058 shares of the medical research company’s stock worth $1,423,000 after acquiring an additional 2,929 shares during the period. Boston Advisors LLC acquired a new position in shares of EXACT Sciences in the second quarter worth approximately $1,971,000. Finally, Dupont Capital Management Corp lifted its stake in shares of EXACT Sciences by 148.9% in the second quarter. Dupont Capital Management Corp now owns 10,710 shares of the medical research company’s stock worth $1,264,000 after acquiring an additional 6,407 shares during the period. Institutional investors own 89.37% of the company’s stock.

In other EXACT Sciences news, Director Katherine S. Zanotti sold 1,744 shares of the business’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $117.93, for a total value of $205,669.92. Following the transaction, the director now directly owns 42,844 shares of the company’s stock, valued at $5,052,592.92. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Jeffrey Thomas Elliott sold 9,845 shares of the business’s stock in a transaction that occurred on Tuesday, July 30th. The shares were sold at an average price of $105.60, for a total value of $1,039,632.00. Following the completion of the transaction, the chief financial officer now directly owns 41,012 shares in the company, valued at $4,330,867.20. The disclosure for this sale can be found here. 2.20% of the stock is currently owned by insiders.

Shares of EXAS opened at $119.82 on Friday. EXACT Sciences Co. has a 52-week low of $47.93 and a 52-week high of $123.99. The company has a debt-to-equity ratio of 0.65, a quick ratio of 2.69 and a current ratio of 2.79. The business’s 50 day moving average price is $116.68 and its two-hundred day moving average price is $101.13. The firm has a market cap of $15.31 billion, a PE ratio of -88.10 and a beta of 1.60.

EXACT Sciences (NASDAQ:EXAS) last issued its quarterly earnings results on Monday, July 29th. The medical research company reported ($0.30) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.56) by $0.26. EXACT Sciences had a negative return on equity of 28.90% and a negative net margin of 35.43%. The firm had revenue of $199.87 million for the quarter, compared to analyst estimates of $182.18 million. During the same period in the previous year, the firm earned ($0.30) earnings per share. The company’s revenue was up 94.3% compared to the same quarter last year. Research analysts predict that EXACT Sciences Co. will post -1.74 EPS for the current fiscal year.

A number of equities analysts recently commented on EXAS shares. BidaskClub lowered EXACT Sciences from a “buy” rating to a “hold” rating in a research note on Wednesday, July 17th. UBS Group lifted their price objective on EXACT Sciences from $120.00 to $143.00 and gave the stock a “buy” rating in a research note on Thursday, August 1st. Craig Hallum lifted their price objective on EXACT Sciences from $115.00 to $127.00 and gave the stock a “buy” rating in a research note on Tuesday, July 30th. BTIG Research lifted their price objective on EXACT Sciences to $130.00 and gave the stock a “buy” rating in a research note on Wednesday, May 1st. Finally, Jefferies Financial Group lifted their price objective on EXACT Sciences from $100.00 to $115.00 and gave the stock a “buy” rating in a research note on Wednesday, May 1st. Two investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. EXACT Sciences presently has a consensus rating of “Buy” and an average target price of $118.91.

EXACT Sciences Company Profile

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.

Read More: How is the discount rate different from the Federal Funds rate?

Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for EXACT Sciences Co. (NASDAQ:EXAS).

Institutional Ownership by Quarter for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.